Search results for "Azoles"

showing 10 items of 899 documents

Pharmacological activity of new histamine analogues.

1974

PyridinesReceptors DrugImmunologyPharmacology toxicologyGuinea PigsMolecular ConformationPharmacologyIn Vitro TechniquesToxicologychemistry.chemical_compoundStructure-Activity RelationshipDogsIleumMedicineAnimalsPharmacology (medical)Heart AtriaPharmacologyAniline Compoundsbusiness.industryImidazolesBiological activityAcetylcholinechemistrybusinessHistamineHistamineMuscle ContractionAgents and actions
researchProduct

Synthesis and preliminary biological evaluation of a new pyridocarbazole derivative covalently linked to a thymidine nucleoside as a potential target…

2003

The therapy of human cancer is one of the more pursued goals by medicinal chemistry research. Most of the compounds clinically used as a treatment owe their efficacy to their cytotoxic interaction (direct or indirect) with nuclear DNA. This interaction results in the inhibition of DNA synthesis and the degradation of nucleic strands. Ellipticine is a naturally occurring 6H-pyrido[4,3-b]carbazole alkaloid endowed with antitumor activity, and several ellipticine derivatives have been used in clinical trials. We previously reported some 1,4-dimethyl-9H-carbazole derivatives structurally related to ellipticine. The purpose of our research was to transform the pyridocarbazole in a prodrug so tha…

PyridonesCarbazolesDrug Evaluation PreclinicalAntineoplastic Agentschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorDrug DiscoveryHumansCytotoxicitynucleoside analogueDNA synthesisBiological activityGeneral ChemistryGeneral MedicineProdrugorganic synthesisPyrimidine NucleosidesBiochemistrychemistryNucleic acidantitumour activityThymidineNucleosideDNAThymidineChemicalpharmaceutical bulletin
researchProduct

Surface-Enhanced Raman Study of the Interactions between Tripodal Cationic Polyamines and Polynucleotides

2011

Raman and surface-enhanced Raman spectra of new DNA/RNA-binding compounds consisting of three imidazole (Im) and three pyridine (Py) rings connected by tripodal polyaminomethylene linkages were obtained by the near-infrared excitation at 1064 nm. Study of interactions of Im and Py polyamines with single-stranded RNA polynucleotides (poly A, poly G, poly C, poly U), double-stranded DNA polynucleotides (poly dAdT-poly dAdT, poly dGdC-poly dGdC) and calf thymus DNA (ct-DNA) by surface-enhanced Raman spectroscopy (SERS) reveals unambiguous enhancement of the Raman scattering from the small molecules as well as appearance of new bands in spectra associated mainly with nucleobases. The SERS exper…

PyrimidinePyridinesStereochemistryGuaninePolynucleotidesSpectrum Analysis RamanBiochemistryAnalytical ChemistryNucleobasechemistry.chemical_compoundsymbols.namesakePolyaminesElectrochemistryAnimalsEnvironmental ChemistryImidazoleSpectroscopyImidazolesAromaticityDNAsurface-enhanced Raman spectroscopy ; polyamines ; polynucleotides ; DNAchemistryPolynucleotidesymbolsRNACattleRaman spectroscopyDNA
researchProduct

An unexpected Dimroth rearrangement leading to annelated thieno[3,2-d][1,2,3]triazolo[1,5-a]pyrimidines with potent antitumor activity.

2013

An unusual Dimroth rearrangement occurring in the reaction leading to annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine core allowed the isolation of the linear isomer thieno[3,2-d][1,2,3]triazolo[1,5-a]pyrimidine. By decorating the linear isomer with the same chains that improved the biological activity of the angular isomers, new annelated thieno[3,2-d][1,2,3]triazolo[1,5-a]pyrimidines were designed and synthesized. They were selected by the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) for the anticancer screening against a panel of 60 human tumor cell lines. The biological results showed that the new derivatives exhibited strong antiproliferative …

PyrimidineStereochemistryAntineoplastic AgentsAnnelated thienotriazolopyrimidines Domino reactions Dimroth rearrangement Developmental Therapeutics Program (DTP) Anticancer agentsDimroth rearrangementD-1chemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryHumansCell ProliferationPharmacologyAntitumor activityLow toxicityDose-Response Relationship DrugMolecular StructureOrganic ChemistryBiological activityGeneral MedicineTriazolesSettore CHIM/08 - Chimica FarmaceuticaHuman tumorPyrimidineschemistryActive compoundDrug Screening Assays AntitumorEuropean journal of medicinal chemistry
researchProduct

New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol

2012

Drug design was performed through the Virtual Lock-and-Key (VLAK) protocol. This in silico approach allowed to select new annelated thienotriazolopyrimidine derivatives, potentially antitumor drugs. Starting from benzothieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine and Pyrido[3',2':4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine core structures, new derivatives of these nuclei were designed and synthesized. Three of them were selected by the Development Therapeutical Program (DTP) of the National Cancer Institute (NCI) for the anticancer screening against a panel of 60 human tumor cell lines. The biological results showed that the new derivatives exhibited an excellent antiproliferative act…

PyrimidineStereochemistryAntineoplastic AgentsThiophenesStructure-Activity Relationshipchemistry.chemical_compoundCell Line TumorDrug DiscoveryHumansStructure–activity relationshipPotencyAnnelated thienotriazolopyrimidines Domino reactions VLAK protocol Developmental Therapeutics Program (DTP) Anticancer agentsCell ProliferationPharmacologyDose-Response Relationship DrugMolecular StructureLow toxicityOrganic ChemistryGeneral MedicineTriazolesCombinatorial chemistrySettore CHIM/08 - Chimica FarmaceuticaHuman tumorPyrimidineschemistryDrug Screening Assays Antitumor
researchProduct

A new pyrazolo pyrimidine derivative inhibitor of cyclooxygenase-2 with anti-angiogenic activity

2003

In a previous study, we reported a new pyrazolo pyrimidine derivative, N(4)-benzyl-N(6),N(6)-dimethyl-1-1(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidine-6,4-diamine (DPP), which inhibited potently cyclooxygenase-2 activity in intact cell assays with minor activity against cyclooxygenase-1 (IC(50)=0.9 nM for cyclooxygenase-2 versus IC(50)=59.6 nM for cyclooxygenase-1). In the present work, this behaviour was confirmed in vivo by using the 24-h zymosan-injected mouse air pouch model (ID(50)=1.36 nM/pouch for prostaglandin E(2) level). We also studied the possible beneficial effect of DPP in the angiogenesis-dependent murine air pouch granuloma and rat paw carrageenan-induced hyperalgesia models. DP…

Pyrimidinemedicine.medical_treatmentAngiogenesis InhibitorsPharmacologyCarrageenanDinoprostoneMicechemistry.chemical_compoundIn vivomedicineAnimalsEdemaCyclooxygenase InhibitorsRats WistarProstaglandin E2IC50NitrobenzenesPharmacologySulfonamidesGranulomaCyclooxygenase 2 InhibitorsNeovascularization PathologicbiologyTumor Necrosis Factor-alphaZymosanRatsIsoenzymesPyrimidinesEicosanoidchemistryBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesHyperalgesiabiology.proteinPyrazolesFemaleCyclooxygenasemedicine.symptomInterleukin-1Prostaglandin Emedicine.drugEuropean Journal of Pharmacology
researchProduct

Predictive modeling of aryl hydrocarbon receptor (AhR) agonism

2020

Abstract The aryl hydrocarbon receptor (AhR) plays a key role in the regulation of gene expression in metabolic machinery and detoxification systems. In the recent years, this receptor has attracted interest as a therapeutic target for immunological, oncogenic and inflammatory conditions. In the present report, in silico and in vitro approaches were combined to study the activation of the AhR. To this end, a large database of chemical compounds with known AhR agonistic activity was employed to build 5 classifiers based on the Adaboost (AdB), Gradient Boosting (GB), Random Forest (RF), Multilayer Perceptron (MLP) and Support Vector Machine (SVM) algorithms, respectively. The built classifier…

Quantitative structure–activity relationshipEnvironmental EngineeringSupport Vector MachineHealth Toxicology and MutagenesisIn silico0208 environmental biotechnologyContext (language use)02 engineering and technologyComputational biology010501 environmental sciences01 natural scienceschemistry.chemical_compoundPhenolsBasic Helix-Loop-Helix Transcription FactorsEnvironmental ChemistryAnimalsHumans[CHIM]Chemical SciencesComputer SimulationBenzothiazolesProspective StudiesReceptorComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciencesRegulation of gene expressionbiologyChemistryPublic Health Environmental and Occupational HealthRobustness (evolution)General MedicineGeneral ChemistryAryl hydrocarbon receptorPollution020801 environmental engineering3. Good healthBenzothiazoleReceptors Aryl Hydrocarbonbiology.proteinNeural Networks Computer[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]Algorithms[CHIM.CHEM]Chemical Sciences/Cheminformatics
researchProduct

Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB.

2004

Clostridium difficile toxin A monoglucosylates the Rho family GTPases Rho, Rac, and Cdc42. Glucosylation leads to the functional inactivation of Rho GTPases and causes disruption of the actin cytoskeleton. A cDNA microarray revealed the immediate early gene rhoB as the gene that was predominantly up-regulated in colonic CaCo-2 cells after treatment with toxin A. This toxin A effect was also detectable in epithelial cells such as HT29 and Madin-Darby canine kidney cells, as well as NIH 3T3 fibroblasts. The expression of RhoB was time-dependent and correlated with the morphological changes of cells. The up-regulation of RhoB was approximately 15-fold and was based on the de novo synthesis of …

RHOAPyridinesRHOBBacterial ToxinsClostridium difficile toxin ARAC1GTPaseBiochemistryp38 Mitogen-Activated Protein KinasesGene Expression Regulation EnzymologicGene productEnterotoxinsStress PhysiologicalRhoB GTP-Binding ProteinHumansrhoB GTP-Binding ProteinMolecular BiologyOligonucleotide Array Sequence AnalysisbiologyImidazolesCell BiologyRhoBClostridium difficileActin cytoskeletonMolecular biologyUp-Regulationbiology.proteinGene expressionCaco-2 CellsThe Journal of biological chemistry
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpo…

2009

Hypertension guidelines advise aggressive blood pressure (BP) lowering in patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Twenty-five thousand five hundred and eighty-eight patients with atherosclerotic disease or diabetes with organ damage, tolerant to angiotensin-converting enzyme inhibitors, were randomized to ramipril, telmisartan or both. We related the primary composite outcome and its components to: baseline SBP; SBP changes from baseline to…

RamiprilMalemedicine.medical_specialtyPhysiologyAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineInternal MedicinemedicineHumansTelmisartanRisk factorAntihypertensive AgentsAgedVascular diseasebusiness.industryMiddle Agedmedicine.diseasePrognosisAngiotensin IISurgeryClinical trialBlood pressureTreatment OutcomeHypertensionCardiologyBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct